ARG

A Rare Disease CRO

2018 Rare Patient Advocacy Conference
 

Everyone Deserves to be Well

ARG is a rare disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. Founded in 2004, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device trial management in diverse and wide-ranging therapeutic areas. ARG has remained true to our original vision: every project is highly significant and visible, delivered through strategic collaboration with partners. ARG is rare for a reason: we successfully operationalize orphan development projects because we believe everyone deserves to be well.

NORTHERA®       Chelsea Therapeutics

The Journey to Droxidopa

Chelsea Therapeutics was in the process of licensing droxidopa for treating neurogenic orthostatic hypotension, but the study suffered from low patient recruitment. ARG was brought in to improve enrollment.


LEARN MORE ›
CINRYZE®       Lev Pharmaceuticals

A Life-saving Drug's Race to America

Cinryze is used to treat hereditary angioedema, or HAE, a genetic defect that results in dysfunctional C1 esterase inhibitor. ARG helped Lev Pharmaceuticals conduct the trials and bring the drug to the market after a troubled history.


LEARN MORE ›
Atlantic Research Group
Community
fuels passion and progress
 

The clinic isn’t the only place where we make strides. ARG works with a variety of rare disease organizations, advancing care alongside other dedicated individuals who advocate research.

 
AcRP
Global Genes
The Hemophilia Alliance
Socra
Histiocytosis Association
Socra
Immune Deficiency Foundation
haea
Interested in Working with ARG?

Submit your request for proposal below.


Verification Code

captcha Get a new code

Please enter the letters as they are shown in the image above. Letters are not case-sensitive.